Cordyceps Sunshine Biotech Holdings (RAJAF) Equity Ratio (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Equity Ratio history runs 6 years deep, the most recent figure standing at 0.11 for Q4 2025.

• In Q4 2025, Equity Ratio fell 41.31% year-over-year to 0.11; the TTM figure through Dec 2025 stood at 0.11 (down 41.31% YoY), while the FY2025 annual figure was 0.11, down 41.31% from the prior year.
• Equity Ratio was 0.11 for Q4 2025 at Cordyceps Sunshine Biotech Holdings, down from 0.08 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.05 in Q4 2023 to a low of 0.45 in Q4 2022.
• Historically, Equity Ratio has averaged 0.15 across 5 years, with a median of 0.09 in 2021.
• The sharpest annual moves came in 2021 and 2023: Equity Ratio plunged 1764.25% in 2021, then surged 89.98% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.08 in 2021, then slumped by 434.71% to 0.45 in 2022, then soared by 89.98% to 0.05 in 2023, then tumbled by 79.34% to 0.08 in 2024, then tumbled by 41.31% to 0.11 in 2025.
• The last three Equity Ratio figures came in at 0.11 (Q4 2025), 0.08 (Q4 2024), and 0.05 (Q4 2023), per Business Quant data.